Grade III Meningioma
Associated Genetic Biomarkers
Grade III meningiomas most frequently harbor alterations in NF2, CDKN2A, CDKN2B, FANCD2, and TERT .
NF2 Mutation, NF2 Nonsense, CDKN2A Loss, NF2fs, and CDKN2B Loss are the most common alterations in grade III meningioma .
There are 4 clinical trials for grade III meningioma, of which 3 are open and 1 is completed or closed. Of the trials that contain grade III meningioma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open).
SSTR2 is the most frequent gene inclusion criterion for grade III meningioma clinical trials .
Novottf-100a device, bevacizumab, and ipilimumab are the most common interventions in grade III meningioma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.